A world leader in the field of
in vitro diagnostics for 45 years,
bioMérieux provides diagnostic solutions (reagents, instruments, software),
which determine the source of disease and contamination to improve
patient health and ensure consumer safety. Its products are used for
diagnosing infectious diseases and providing high medical-value results
for cardiovascular emergencies and cancer screening and monitoring.
They are also used for detecting microorganisms in agri-food,
pharmaceutical and cosmetic products.
bioMérieux is present in over 150 countries through 38 subsidiaries
and a large network of distributors. The company has more than
5,700 employees throughout the world. In 2007, revenues reached
1.063 billion euros with 84% of sales outside of France.
bioMérieux is listed on NYSE Euronext Paris.